KevinCompounds said:Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…
That holds where the measurement is reliable. Where it is noisy — and a lot of what gets tracked here is noisy — the same reasoning produces confident nonsense.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
KevinCompounds said:Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…
This is where I part company with the consensus forming above. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.
Ask again with the specifics and you will get a better answer than this one.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsAdding the numbers, since they settle part of this. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.
Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source.